Finance

Beta
Lists
SGMT:NASDAQ
Sagimet Biosciences Inc
$7.02
-0.57%
(-0.040) 1D
Jun 29, 11:13:16 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SGMT...
Open
$6.97
High
$7.16
Low
$6.97
Mkt. cap
433.50M
Avg. vol.
1.17M
Volume
182.69K
52-wk high
$11.41
52-wk low
$4.50
EPS
-$1.34
Shares outstanding
61.18M
No. of employees
16
Open
$6.97
High
$7.16
Low
$6.97
Mkt. cap
433.50M
Avg. vol.
1.17M
Volume
182.69K
52-wk high
$11.41
52-wk low
$4.50
EPS
-$1.34
Shares outstanding
61.18M
No. of employees
16
News stories
From sources across the web
About Sagimet Biosciences Inc
CEO-
Employees16
Founded2006
HeadquartersSan Mateo, California, United States
SectorBiotechnology
Websitesagimet.com
Analyst ratings
Based on 10 analysts giving stock ratings to SGMT in the past 3 months
Strong buy
Buy
9
Hold
1
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for SGMT in the last 3 months.
Highest
Current $7.02
$49.00 (+598.01%)
Average
$25.90 (+268.95%)
Lowest
$8.00 (+13.96%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yun Zhong
Wedbush
Buy
Maintained
$28.00
+298.9%
06/22/2026
Brandon Folkes
H.C. Wainwright
Buy
Maintained
$29.00
+313.1%
05/26/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$12.00
+70.9%
05/19/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
$26.00
+270.4%
05/14/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$28.00
+298.9%
05/13/2026
Edward Nash
Canaccord Genuity
Buy
Maintained
$49.00
+598%
05/12/2026
Ritu Baral
TD Cowen
Buy
Maintained
$21.00
+199.1%
05/12/2026
Jay Olson
Oppenheimer
Buy
Reiterated
$33.00
+370.1%
05/01/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
$25.00
+256.1%
04/29/2026
Eliana Merle
Barclays
Hold
Maintained
$8.00
+14%
04/02/2026
Unknown Analyst
Rodman & Renshaw
Buy
Initiated
$28.00
+298.9%
03/26/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
$28.00
+298.9%
03/26/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
7.25M
9.73M
6.73M
7.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.68M
4.60M
4.03M
4.72M
Operating expense
11.92M
14.33M
10.76M
11.71M
Total operating expenses
11.92M
14.33M
10.76M
11.71M
Operating income
-11.92M
-14.33M
-10.76M
-11.71M
Other non operating income
-
-
-
-
EBT including unusual items
-10.39M
-12.91M
-9.57M
-10.65M
EBT excluding unusual items
-10.39M
-12.91M
-9.57M
-10.65M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-10.39M
-12.91M
-9.57M
-10.65M
Net profit margin
-
-
-
-
Earnings per share
-0.32
-0.40
-0.29
-0.33
Interest and investment income
1.54M
1.43M
1.20M
1.06M
Interest expense
-
-
-
-
Net interest expenses
1.54M
1.43M
1.20M
1.06M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of SGMT
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer